Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | MIF | P14174 | 1/20 | 0.61 |
| ▸ | TYR | P14679 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.54 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30621344 | 0.98 | ALDH1A1 (0.59) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL5480761 | 0.92 | ALDH1A1 (0.64) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL11314238 | 0.86 | ALDH1A1 (0.45) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL7768449 | 0.84 | ALDH1A1 (0.53) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL8387655 | 0.83 | ALDH1A1 (0.42) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL12731992 | 0.82 | ALDH1A1 (0.54) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL12803903 | 0.81 | NR3C1 (0.41) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL2790854 | 0.80 | ALDH1A1 (0.55) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL23772413 | 0.79 | ALDH1A1 (0.39) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL23964558 | 0.79 | NR3C1 (0.43) | ALDH1A1ALOX15HSD17B10LMNANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| JP-2300143-A | — | — | None | — | — | JP | disclosed |
| CN-122037020-A | Supported catalyst, preparation method thereof and application thereof in olefin polymerization | 中国石油化工股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12617880-B2 | Compounds for use in catalyst compositions for the production of polyolefins | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| WO-2025217552-A1 | 2-(TERT-BUTYL)-4-METHYLPHENYL APPENDED 1,4-DIAZEPANE BASED NOVEL TFEB ACTIVATING COMPOUNDS AS AUTOPHAGY MODULATORS FOR NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S DISEASE (AD) | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-10-16 | — | — | WO | disclosed |
| US-12291593-B2 | Compounds for use in catalyst compositions for the production of polyolefins | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2025-05-06 | — | — | US | disclosed |
| EP-4031592-B1 | COMPOUNDS FOR USE IN CATALYST COMPOSITIONS FOR THE PRODUCTION OF POLYOLEFINS | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2025-04-30 | — | — | EP | disclosed |
| US-12215181-B2 | Anionic group III complexes as weakly coordinating anions for olefin polymerization catalyst activators | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-02-04 | — | — | US | disclosed |
| CN-114423769-B | Compounds in catalyst compositions for the production of polyolefins | SABIC环球技术有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-112679635-B | Preparation method of supported metallocene catalyst and catalyst prepared by preparation method | 中国石油化工股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1675839-B1 | STEREOSELECTIVE SYNTHESIS OF CERTAIN TRIFLUOROMETHYL-SUBSTITUTED ALCOHOLS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007075946-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075946-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1773816-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006002421-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
| JP-H02300143-A | PRODUCTION OF FLUOROPHENOLS | SUMITOMO CHEM CO LTD | 1990-12-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617880-B2 | Compounds for use in catalyst compositions for the production of polyolefins | PRMT5, CBR3, MET | ALDH1A1 1762/4885ALOX15 876/4885HSD17B10 1162/4885 |
| US-12215181-B2 | Anionic group III complexes as weakly coordinating anions for olefin polymerization catalyst activators | YAP1, AP1G1, AP1M1 | ALDH1A1 1472/4885ALOX15 277/4885HSD17B10 1767/4885 |
| US-12291593-B2 | Compounds for use in catalyst compositions for the production of polyolefins | RPLP0, RPS20, RPS10 | ALDH1A1 1508/4885ALOX15 744/4885HSD17B10 734/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | ALDH1A1 2651/4885ALOX15 3295/4885HSD17B10 1678/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | ALDH1A1 2221/4885ALOX15 3245/4885HSD17B10 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.